Bioequivalence study of Famotidine 40 mg tablet
Not Applicable
Recruiting
- Conditions
- In the present study, the products will be administered to healthy volunteers.
- Registration Number
- IRCT20210519051345N32
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
General Health (in terms of Liver, Heart and Kidney)
Age (18-59 years)
Exclusion Criteria
Smoking
History of cardiovascular disease, liver and kidney disease
Pregnancy
Alcohol and drug addiction
History of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of drug. Timepoint: 0.5-12 hours in predetermined time intervals after drug administration. Method of measurement: HPLC (High performance liquid chromatography).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Famotidine's action on H2 receptors in healthy volunteers?
How does the bioequivalence of generic Famotidine compare to the innovator drug in clinical trials?
Are there specific biomarkers that predict gastrointestinal response to Famotidine therapy?
What are the potential adverse events associated with Famotidine 40 mg tablet formulations?
What is the therapeutic landscape of H2 receptor antagonists in comparison to PPIs for acid-related disorders?